Either PKD1 or PKD2 variants may be associated with cardiomyopathy,74 but idiopathic dilated cardiomyopathy is more commonly associated with PKD2 disease-causing variants.74,75 Although most medications for management of heart failure are safe in ADPKD, sodium-glucose cotransporter-2 inhibitor (SGLT2i) could be used after a careful consideration of the individual risks and benefits for a patient.76Treatment with an SGLT2i may stimulate vasopressin and thus be detrimental patients with for ADPKD. Here, SLC5A2 is linked to autosomal dominant polycystic kidney disease.